DB
XGN icon

Dmitry Balyasny’s Exagen XGN Stock Holding History

Dmitry Balyasny’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-796,632
Closed -$2.39M – 3564
2026
Q1 		$2.39M Sell
796,632
-122,555
-13% -$474K ﹤0.01% 1704
2025
Q4 		$5.59M Buy
919,187
+195,759
+27% +$1.78M 0.01% 1337
2025
Q3 		$7.95M Buy
723,428
+4,646
+0.6% +$41.1K 0.01% 1173
2025
Q2 		$5.02M Buy
+718,782
New +$4.37M 0.01% 1295

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Dmitry Balyasny's XGN Position: Q2 2026 in Review

Dmitry Balyasny sold out of Exagen (XGN) in Q2 2026, closing a stake of 796,632 shares — an estimated $2.39M sold.

Dmitry Balyasny first reported a position in XGN in Q2 2025 and held it in 4 quarters. The position peaked at $7.95M in Q3 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Dmitry Balyasny reported no remaining Exagen position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 796,632 Exagen shares in Q2 2026, an estimated $2.39M.
  • Dmitry Balyasny first reported a position in Exagen in Q2 2025 and held it in 4 quarters.
  • Dmitry Balyasny's Exagen position peaked at $7.95M in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.